reviewed april 2026|next review october 2026|88 physicians psi has verified|3178 published studies
Follistatin
Follistatin is a naturally occurring (the body's own) glycoprotein that binds and neutralizes myostatin (the hormone that limits muscle growth), with gene therapy trials (AAV1-FS344) showing functional improvements in inclusion body myositis and muscular dystrophy patients.
Evidence landscape: 3178 published studies
3,178 published items. 22 human studies and 153 animal studies. Extensive mechanistic data with a critical distinction between gene therapy and injectable evidence.
- 22 Human
- 153 Animal
- 25 Reviews
- 2978 Other research
Blocks myostatin (GDF-8) and activin. The 'mighty mouse' experiments validated the biology: myostatin-knockout mice develop approximately twice normal muscle mass.
Gene therapy trials (AAV1-FS344) showed functional improvements in inclusion body myositis and Becker muscular dystrophy patients. Injectable peptide form has not been tested in humans.
Gene therapy uses sustained viral vector expression. Injectable peptide has a short half-life and uncertain tissue distribution. The pharmacokinetic gap is substantial.
PSI Assessment
Block the hormone that limits muscle growth, and muscle grows beyond normal limits - the 'mighty mouse' experiments proved the concept decades ago. Follistatin is the body's own myostatin inhibitor, and gene therapy trials delivering it via viral vector have shown functional improvements in patients with muscular dystrophy and inclusion body myositis. The critical distinction for anyone researching follistatin is that the human evidence comes from gene therapy delivery, not from the injectable form available through peptide suppliers. That pharmacokinetic gap is the central unresolved question.
Block the hormone that limits muscle growth. Gene therapy trials show functional improvements. The injectable peptide form has not been tested in humans.
The mechanism is high-affinity binding of myostatin (GDF-8) and activin, preventing their engagement with activin type II receptors and blocking downstream Smad2/3 signaling. The 'mighty mouse' experiments, where myostatin knockout mice developed approximately twice normal muscle mass, validated the biology. Multiple follistatin isoforms (FS288, FS303, FS315) have different tissue distribution and heparin-binding properties. Follistatin also regulates FSH through activin inhibition, connecting muscle biology to the reproductive axis.
What the evidence supports
Follistatin binds and neutralizes myostatin with high affinity, preventing muscle growth limitation. Gene therapy delivery (AAV1-FS344) has shown functional improvements in patients with inclusion body myositis and Becker muscular dystrophy in controlled trials. Myostatin biology is validated by the dramatic phenotype of myostatin-knockout animal models. Over 3,100 published studies document the mechanism.
What is not yet established
Whether injectable follistatin produces clinically meaningful muscle effects in humans. The gene therapy trials use sustained viral vector expression, not short-half-life injectable peptide. Whether the pharmacokinetic gap between gene therapy and injectable delivery can be bridged. Optimal dosing of injectable follistatin for myostatin inhibition.
Research Evidence
The findings below cover the gene therapy human trials, the myostatin mechanism, and the pharmacokinetic gap between gene therapy and injectable delivery.
Evidence by condition
Evidence dimensions across follistatin's investigated applications. Reproductive biology has the deepest human evidence. Muscle growth data is strongest from gene therapy trials, not injectable peptide.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Reproductive Biology | ||||
| Muscle Growth/Wasting | ||||
| Hair Growth | ||||
| Fibrosis |
Gene therapy trials (AAV1-FS344) in patients with inclusion body myositis and Becker muscular dystrophy showed improvements in functional endpoints including 6-minute walk distance and reduced endomysial fibrosis on muscle biopsy.
The gene therapy approach produces sustained local follistatin expression for weeks to months. This is fundamentally different from injectable peptide pharmacokinetics.
Myostatin-knockout animal models develop approximately twice normal muscle mass. Follistatin overexpression produces similar dramatic muscle hypertrophy in animal models.
The myostatin inhibition concept is one of the most validated in muscle biology. The question is not whether the mechanism works but whether injectable delivery achieves sufficient tissue concentrations.
Injectable follistatin peptide has a short circulating half-life and uncertain tissue penetration. No published study has specifically tested injectable follistatin for muscle hypertrophy in humans.
The pharmacokinetic gap between gene therapy (sustained local expression) and injectable peptide (short half-life, systemic distribution) is the central limitation for anyone considering the injectable form.
22 Human|153 Animal|25 Reviews
View all 3178 indexed studiesHow Follistatin Works
Follistatin is a naturally occurring (the body's own) glycoprotein that acts as a potent inhibitor of activin, myostatin, and other members of the TGF-beta superfamily. Multiple isoforms exist with different tissue distribution.
Your body has a built-in limit on how much muscle it can grow, controlled by a protein called myostatin. Follistatin works by binding to myostatin and preventing it from sending its 'stop growing' signal. With myostatin blocked, muscle cells can grow larger and multiply more freely. Follistatin also blocks a related protein called activin, which plays roles in inflammation and reproductive hormone signaling.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Follistatin binds directly to activin and myostatin (GDF-8) with high affinity, preventing them from activating their type II serine/threonine kinase receptors (ActRIIA/B). This blocks the downstream Smad2/3 signaling cascade that normally limits muscle fiber hypertrophy. Multiple isoforms exist: FS288 (heparin-binding, locally acting), FS303 (gonadal-specific), and FS315 (circulating form). In reproductive biology, follistatin's inhibition of activin reduces FSH secretion from the anterior pituitary.
What is Follistatin being studied for?
Researchers are studying Follistatin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Follistatin overall. This means a compound can have human studies for one condition but only animal data for another.
Reproductive Biology
·Human TrialsFollistatin's role in FSH regulation and reproductive physiology is well-established through decades of endocrine research. It is a key regulator of the activin-inhibin-follistatin axis.
Limitations: Therapeutic applications in reproductive medicine are limited by the complexity of the activin-inhibin-follistatin axis. Exogenous follistatin administration for fertility purposes has not been validated in clinical trials.
Muscle Growth/Wasting
·Animal StudiesGene therapy delivery of follistatin has been tested in humans with neuromuscular disease, showing functional improvements. Injectable peptide data for muscle growth in humans does not exist.
Limitations: Gene therapy is not equivalent to injectable peptide therapy. The pharmacokinetic profiles are fundamentally different.
Hair Growth
·PreclinicalFollistatin has been identified in hair follicle signaling, and some data from animal studies suggests a role in hair cycle regulation.
Limitations: No clinical trials for hair growth. The evidence is observational and mechanistic only.
Fibrosis
·PreclinicalActivin signaling promotes fibrosis in multiple organs. Follistatin's inhibition of activin has theoretical anti-fibrotic potential, supported by animal model data.
Limitations: All fibrosis data is from animal studies. Anti-fibrotic human trials have not been conducted.
Safety and Regulatory Status
FDA Status: Not FDA-approved for any indication. Gene therapy approaches using follistatin are in clinical development with formal FDA investigational authorization.
Availability: Not on any FDA list that limits pharmacy preparation. Injectable peptide is available through research suppliers and some pharmacies.
Safety context: Follistatin is a naturally occurring (the body's own) glycoprotein. Gene therapy trials reported acceptable safety in small populations. Injectable peptide safety in humans has not been formally studied.
Gene therapy trials reported mild injection site reactions and transient creatine kinase elevations. No serious adverse events attributed to follistatin expression. Injectable peptide-specific side effect data in humans does not exist.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Follistatin discussion.
Comparison and Related Research
Follistatin is most often compared with other approaches to the myostatin pathway.
Head-to-head comparisons
Full research comparisons covering Follistatin and another peptide side by side.
Follistatin vs Myostatin Inhibitors (Bimagrumab)
Follistatin binds multiple targets including myostatin. Pharmaceutical antibodies target myostatin specifically. Evidence-graded comparison for muscle research.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.This landmark study demonstrated that overexpression of follistatin in transgenic mice produces a dramatic increase in muscle mass, comparable to the effect of myostatin gene deletion. Mice expressing the follistatin transgene showed a 194-327% increase in individual muscle weights, establishing follistatin as the most potent known inhibitor of myostatin signaling and a key regulator of muscle growth.Lee SJ, McPherron AC, 2001 in Proc Natl Acad Sci U S A. View on PubMed
- 2.A Phase 1/2a gene therapy trial delivered AAV1-FS344 (a viral vector carrying follistatin) directly into the quadriceps muscles of patients with Becker muscular dystrophy. At six months, participants showed improvements in the six-minute walk test and muscle biopsy analysis revealed reduced fibrosis and increased muscle fiber size, supporting the concept of follistatin gene therapy for muscle disease.Mendell JR et al., 2015 in Mol Ther. View on PubMed
- 3.A comprehensive review examining the therapeutic potential of myostatin inhibition through follistatin and related strategies for treating muscular dystrophies and other muscle-wasting conditions. The review covers preclinical data from multiple animal models showing that follistatin gene delivery can increase muscle mass, reduce pathology, and improve functional outcomes in models of Duchenne and limb-girdle muscular dystrophy.Rodino-Klapac LR et al., 2009 in Muscle Nerve. View on PubMed
- 4.This structural biology study solved the crystal structure of the follistatin-activin complex, revealing how follistatin wraps around activin to block both type I and type II receptor binding sites simultaneously. The structure explains the high affinity and near-irreversible nature of follistatin's antagonism, providing the molecular basis for why follistatin is such an effective inhibitor of activin and related TGF-beta superfamily ligands.Thompson TB et al., 2005 in Dev Cell. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.